Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Cash & Equivalents (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Cash & Equivalents for 3 consecutive years, with $31.2 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 28.22% to $31.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.2 million through Dec 2025, down 28.22% year-over-year, with the annual reading at $31.2 million for FY2025, 28.22% down from the prior year.
  • Cash & Equivalents hit $31.2 million in Q4 2025 for Compass Therapeutics, down from $46.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $46.8 million in Q3 2025 to a low of $19.3 million in Q2 2023.
  • Historically, Cash & Equivalents has averaged $30.6 million across 3 years, with a median of $28.7 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: surged 79.47% in 2024 and later dropped 28.22% in 2025.
  • Year by year, Cash & Equivalents stood at $24.2 million in 2023, then surged by 79.47% to $43.5 million in 2024, then fell by 28.22% to $31.2 million in 2025.
  • Business Quant data shows Cash & Equivalents for CMPX at $31.2 million in Q4 2025, $46.8 million in Q3 2025, and $22.9 million in Q2 2025.